| How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden? | 02/04/2025 | |
| Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combi… | 02/02/2025 | |
| Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for F… | 02/04/2025 | |
| Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congre… | 02/04/2025 | |
| What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers? | 02/04/2025 | |
| What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers? | 02/02/2025 | |
| HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivi… | 02/03/2025 | |
| Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Direct… | | |
